about
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and BeyondPfCRT and its role in antimalarial drug resistanceBiochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseMolecular Mechanisms for Drug Hypersensitivity Induced by the Malaria Parasite's Chloroquine Resistance TransporterA lactate and formate transporter in the intraerythrocytic malaria parasite, Plasmodium falciparumThe Malaria Parasite's Lactate Transporter PfFNT Is the Target of Antiplasmodial Compounds Identified in Whole Cell Phenotypic ScreensDiverse chemotypes disrupt ion homeostasis in the Malaria parasite.(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite.Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparumAn acid-loading chloride transport pathway in the intraerythrocytic malaria parasite, Plasmodium falciparum1H-NMR metabolite profiles of different strains of Plasmodium falciparum.Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT.Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter.Degrees of chloroquine resistance in Plasmodium - is the redox system involved?Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.Chloroquine resistance-conferring mutations in pfcrt give rise to a chloroquine-associated H+ leak from the malaria parasite's digestive vacuole.Membrane transport in the malaria parasite and its host erythrocyte.Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the Plasmodium falciparum Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs.Efflux of a range of antimalarial drugs and 'chloroquine resistance reversers' from the digestive vacuole in malaria parasites with mutant PfCRT.A verapamil-sensitive chloroquine-associated H+ leak from the digestive vacuole in chloroquine-resistant malaria parasites.Bacteriophage-encoded glucosyltransferase GtrII of Shigella flexneri: membrane topology and identification of critical residuesCholine uptake into the malaria parasite is energized by the membrane potential.Feedback inhibition of pantothenate kinase regulates pantothenol uptake by the malaria parasite.A polymorphic drug pump in the malaria parasite.A forward genetic screen identifies a negative regulator of rapid Ca2+-dependent cell egress (MS1) in the intracellular parasite Toxoplasma gondii.Diverse antimalarials from whole-cell phenotypic screens disrupt malaria parasite ion and volume homeostasis.Biochemical characterization and chemical inhibition of PfATP4-associated Na-ATPase activity in membranesDefense Peptides Engineered from Human Platelet Factor 4 Kill Plasmodium by Selective Membrane DisruptionCell Swelling Induced by the Antimalarial KAE609 (Cipargamin) and Other PfATP4-Associated AntimalarialsA 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4
P50
Q27826351-E48A1BA0-0EC8-43A3-920F-B2DA4F50DAB6Q27861957-0A4D4659-8E93-4ECF-BC62-0B801A7B0319Q28468285-A0AEB30E-91E8-41C2-863C-9FB6E551C93FQ28552775-1E4AB4FA-9270-47DC-AD80-12B875BA86A6Q30042958-ECC29CCF-2E6B-4111-B65A-1EFC634AA70BQ30042965-C61E88D6-7157-4483-9967-4BE488D669FCQ30487225-4C9D06E9-E3D6-4B0C-B1EA-91148A302A22Q30610467-773E1844-1A4B-4F0E-B0FA-3E17FEC865A6Q33360888-E99C59E9-EC3D-4301-9591-12CE8DA04824Q33636449-CFE5B36D-B7A5-4150-81E9-F38002207FB4Q33797050-6F631F8B-7BE1-4758-8A59-84C5CA1D3B78Q33897865-3016FBFE-C422-4D6F-B733-B4B54FBBE26FQ34554760-35FB094E-521F-4256-81E0-66777749547DQ34932500-D94D2539-B406-4123-A415-374395E30C89Q35879787-5CE0F6A3-EA76-4BFD-9BB5-96B5F6D644C3Q36072626-3C2E7774-326B-486F-9B75-947A5D9DA8E4Q36919648-1F82851A-3899-47B6-8E52-E1A289BBC513Q36993537-6A73EC19-56AA-430B-9306-CD11B2B35B6CQ38170172-1133E2A3-ECB6-4123-8B44-FDD39E6D3187Q41916522-FEC92FE6-0038-41CA-B03E-568E7125C7C5Q41935526-1BD27C07-190A-459B-9574-A6C5849E0DAAQ41940999-CB5DC51C-C947-4E75-8854-B1843E16B05DQ42755366-4AC629CD-4725-45CF-898C-323E519023E0Q44953570-63862781-60F0-48F4-BC6B-C795BD2A31E0Q47836186-0B532EEC-C04E-4539-B8DF-B3018F027015Q47887041-E8FC39B4-8F0E-4154-B822-E1A78BE1C9E9Q48165990-471B399D-488F-45DA-99CA-559A6F1F0473Q55334152-8535B6B3-6341-47DD-B8AB-C02B87C573A0Q56341251-DDB50A66-3E63-4103-881B-E558B412E5A9Q56364460-1D5C7F04-411B-43A7-A237-7F208C58F038Q56379943-B1A3DC2E-1669-4CC2-A27B-959B70AD0322Q91936969-61710034-5D7C-4720-B4DB-44BE72C3AA02
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adele M Lehane
@ast
Adele M Lehane
@en
Adele M Lehane
@es
Adele M Lehane
@nl
Adele M Lehane
@sl
type
label
Adele M Lehane
@ast
Adele M Lehane
@en
Adele M Lehane
@es
Adele M Lehane
@nl
Adele M Lehane
@sl
prefLabel
Adele M Lehane
@ast
Adele M Lehane
@en
Adele M Lehane
@es
Adele M Lehane
@nl
Adele M Lehane
@sl
P106
P21
P31
P496
0000-0002-0050-9101